Mesoblast limited  

(Public, ASX:MSB)   Watch this stock  
1.02
-0.01 (-1.45%)
Jun 29 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 1.02 - 1.05
52 week 1.02 - 4.06
Open 1.05
Vol / Avg. 706,881.00/1.25M
Mkt cap 389.00M
P/E     -
Div/yield     -
EPS -0.33
Shares 381.37M
Beta     -
Inst. own     -
Aug 15, 2016
Preliminary 2016 Mesoblast Ltd Earnings Release (Estimated) Add to calendar
May 10, 2016
Q3 2016 Mesoblast Ltd Earnings Release
May 10, 2016
Q3 2016 Mesoblast Ltd Earnings Presentation
May 4, 2016
Mesoblast Ltd at Deutsche Bank Health Care Conference
Apr 28, 2016
Mesoblast Ltd KPI Quarterly Report - March 2016
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -408.81% -502.64%
Operating margin -447.83% -514.60%
EBITD margin - -506.37%
Return on average assets -8.70% -12.16%
Return on average equity -13.98% -19.68%
Employees 115 -
CDP Score - -

Address

L 38 55 Collins St
MELBOURNE, VIC 3000
Australia
+61-3-96396036 (Phone)
+61-3-96396030 (Fax)

Website links

Description

Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates, which represents its lead programs where it focuses on time and resources, such as MPC-06-ID, MPC-150-IM, JR-031, MPC-300-IV and MSC-100-IV, and tier 2 product candidates, which advances to tier 1 depending on newly-generated data, market opportunity or partnering options, such as MSC-100-IV, MPC-25-IC, MPC-25-Osteo and MPC-CBE.

Officers and directors

Silviu Itescu Chief Executive Officer, Executive Director
Paul Hodgkinson Group Chief Financial Officer
Charlie Harrison Company Secretary
Brian Jamieson Independent Non-Executive Chairman of the Board
William Burns Non-Executive Independent Director
Donal Paul O'Dwyer Non-Executive Independent Director
Age: 62
Eric A. Rose M.D. Non-Executive Independent Director
Age: 64
Michael R. Spooner Non-Executive Independent Director